cGxP.wire https://validator.w3.org/feed/docs/rss2.html Jazz and AbCellera Partner on Next-Gen Cancer Antibodies Diazyme Laboratories Secures FDA Clearance for Lp(a) Assay TrialAssure and Cancer Research UK Partner on AI Regulatory Authoring Denali Therapeutics to Sell FDA Priority Review Voucher for $195M Merck’s CAPVAXIVE Wins FDA Approval for High-Risk Children Allarity Therapeutics Showcases Phase 2 Stenoparib Trial Design at ESMO 2026 Curium Court Victory Clears Path for U.S. GEP-NET Therapy Prime Medicine Receives New Zealand CTA Clearance for PM577a in Wilson Disease SK pharmteco Partners With OTXL to Advance Rare Therapies Genentech FDA Filing Advances Lunsumio-Polivy in LBCL FDA Approves First Generic Xofluza for Influenza Treatment Mabwell Showcases Strong 9MW2821 Cervical Cancer Data AVITA Medical Reports First U.K. Clinical Success with RECELL GO GSK and Spero Secure FDA Nod for First Oral Carbapenem GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 in IPF MAIA Biotechnology Expands THIO-101 Trial with Winship Enrollment Biogen Signs Landmark RayThera Acquisition Worth Up to $1 Billion Longeveron Reports New Phase 2a Laromestrocel Alzheimer’s Data LabGenius and LG Chem Partner on AI-Designed Cancer Antibodies AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Cadrenal Therapeutics to Seek FDA Rare Pediatric Designation Samsung Bioepis and Organon Expand PYZCHIVA Rights in Canada Boehringer Ingelheim Reports Survival Gains With Nerandomilast LIR Shows Successful Needle-Free Delivery of GLP-1 Therapies Lupin Launches Azilsartan Medoxomil Tablets in U.S. Market TORL BioTherapeutics Reports Promising Ovarian Cancer Data Insilico Medicine Reports First Human Dosing of ISM8969 Corcept Resubmits Relacorilant NDA for Cushing’s Syndrome to FDA Alkermes Highlights Strong Phase 2 Data for Alixorexton at SLEEP 2026 Verastem Oncology Shows Encouraging Survival Data in RAMP 205 Pancreatic Cancer Trial F2G and Shionogi Report Positive Phase 3 OASIS Results D&D Pharmatech Phase 2 MASH Data Shows Strong Fibrosis Gains VahatiCor Enrolls First U.S. Patient in A-FLUX SERRA-I Trial Acurx Pharmaceuticals Showcases DNA pol IIIC Antibiotic Breakthrough Roche Secures FDA sBLA Acceptance for Lunsumio VELO Combination CTAD and ADDF Unite to Accelerate Alzheimer’s Innovation Verastem Oncology Doses First Patient in TARGET-D 201 Trial Vedana Therapeutics Raises $46 Million to Advance Migraine Therapies NMD Pharma Reports Positive Phase 2a Ignaseclant Data in CMT UCB Reports Positive KYGEVVI Outcomes in TK2d Patients Skin Tech Pharma Group Wins Best Injectable at AMWC 2026 Resolution Therapeutics Expands Regenerative Macrophage Therapy with In Vivo Platform Bristol Myers Squibb Declares Quarterly Dividend Payment Assertio Finalizes Merger with Zydus Lifesciences and Delists from Nasdaq Triveni Bio Secures $65M to Advance TRIV-573 Development FiberSense CGM System Achieves CE Mark for Market Launch Protillion Biosciences Partners With Merck on AI Drug Discovery Simulations Plus to Join Altaris in $375M Acquisition Deal IASO Bio Secures Singapore Approval for FUCASO CAR-T Elanco Launches $25M Ventures Fund for Animal Health